January 8, 2019
Kyowa Hakko Kirin said on January 7 that it has filed a new drug application in Japan for its anti-FGF23 monoclonal IgG1 antibody burosumab, otherwise known as KRN23, for the treatment of FGF23-related hypophosphatemic rickets and osteomalacia. Designated as an...read more